1. Home
  2. NXDT vs VTYX Comparison

NXDT vs VTYX Comparison

Compare NXDT & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexPoint Diversified Real Estate Trust

NXDT

NexPoint Diversified Real Estate Trust

HOLD

Current Price

$3.29

Market Cap

170.0M

Sector

Finance

ML Signal

HOLD

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$8.17

Market Cap

713.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXDT
VTYX
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.0M
713.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NXDT
VTYX
Price
$3.29
$8.17
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.60
AVG Volume (30 Days)
133.6K
1.7M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
9.66%
N/A
EPS Growth
N/A
N/A
EPS
0.99
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.89
$0.78
52 Week High
$13.07
$10.55

Technical Indicators

Market Signals
Indicator
NXDT
VTYX
Relative Strength Index (RSI) 60.09 47.12
Support Level $2.65 $8.39
Resistance Level $3.70 $9.13
Average True Range (ATR) 0.23 0.63
MACD 0.08 -0.25
Stochastic Oscillator 63.30 20.35

Price Performance

Historical Comparison
NXDT
VTYX

About NXDT NexPoint Diversified Real Estate Trust

NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: